Transparency Market Research

Global Diagnostic Testing of STDs Market Is Expected to Reach an Estimated Value of US $108.5 Billion by the End of 2019

Transparency Market Research Announced Report Title "Diagnostic Testing of STDs Market (Laboratory Testing, Point-Of-Care Testing, Laboratory Equipment and Supplies) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" And Its Full Database.


Albany, NY -- (SBWIRE) -- 08/28/2015 -- Sexually Transmitted Diseases (STDs), also known as sexually transmitted infections (STIs), or venereal diseases (VDs) are diseases that spread majorly through person-to-person sexual contact. Indicative testing of STDs refers to testing technologies that are used for examining and identifying the type of STD. Diagnostic testing of STDs is typically done in the laboratories or at the point-of-care (POC). Sexually transmitted diseases (STDs) could be caused by more than 30 distinctive viruses, parasites, and bacteria and are essentially spread by sexual contact and at times by non-sexual means. Diagnostic testing for STDs is regarded as being particularly crucial since these can have serious effects on sexual and reproductive wellbeing - extending from infertility and pelvic inflammatory diseases to AIDS and cervical cancer.

Browse Full Global Diagnostic Testing of STDs Market Research Report With Complete TOC @

The global diagnostic testing of STDs market was estimated at US$65.9 billion in 2012, and is expanding at high CAGR of 8.1% through the forecast horizon 2013 to 2019. The market is expected to reach an estimated value of US$108.5 billion by the end of 2019.

HPV-Caused Cancer: The Most Common Cervical Cancer in Women
The most extensive STDs are P&S syphilis, chlamydia, gonorrhea, genital herpes (causative agent - Herpes Simplex Virus (HSV)), chancroid, AIDS (causative agent - HIV), anal cancer, vulval/vaginal cancer, genital warts, cervical cancer, some types of oral and throat cancers (causative agent - Human Papilloma Virus (HPV)), and penal cancer.

The most common cervical cancer in women is the HPV-caused cancer. It is estimated that HPV infection causes 500,000 instances of cervical cancer globally every year. Consistently around 300,000 cervical cancer deaths are recorded because of HPV. Therefore, HPV testing is a quickly developing market that is predicted to expand at a high CAGR of more than 70% during the forecast horizon 2013 to 2019.

The HPV market is segmented into two categories: High-risk HPV and low-risk HPV, which manifests in the form of warts. The latter is usually not diagnosed via PoC methods, and may need specialized laboratory tests.

Implications of Undiagnosed STDs
Undiagnosed STDs can have dangerous implications on reproductive, maternal and infant wellbeing. For instance, 10%-15% of women with untreated Chlamydia disease can develop symptomatic pelvic inflammatory disease (PID).

About 10% to 15% of PID cases progress into tubal factor infertility. Human Papilloma Virus (HPV) is the causative agent for 99% of cervical cancers in women. Additionally, HPV infection brings about 500,000 instances of cervical cancer and 300,000 deaths due to cervical cancer every year. Undiagnosed and untreated STDs, such as Syphilis lead to Congenital Syphilis which results in pre-term labor with associated dangers of pre-term conception, low birth weight, lack of sight and death of the neonate. Worldwide, more than 1 million instances of Syphilis take place among pregnant women and a large number of these were untreated or insufficiently treated. Unless testing and treatment of Syphilis in pregnancy are promptly accessible, more than 50% of the pregnancies in women with Syphilis will bring about detrimental outcomes as expressed previously.

Geographically, the global diagnostic testing of STDs market can be segmented into North America, the Asia Pacific, Latin America, and Europe. STDs can broadly be categorized as STDs of the regions which are developed and STDs of the regions which are poor/ developing. As STDs such as Chlamydia, Gonorrhea and P&S Syphilis are more common in North America and Europe, these developed regions possess a greater market share on the basis of testing volume for these diseases. Due to the fact that a number of the viral STDs find origin in the developing/poor regions of RoW, these regions have earned a higher market share on the basis of testing volume of STDs such as HIV, HSV, and Chancroid.

The key market players in the global diagnostic testing of STDs market are BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.

Request For Sample Report:

About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:
Mr. Nachiket Ghumare
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
Tel: 518-618-1030
USA - Canada Toll Free: 866-552-3453